PAMP
IMVT icon

Polar Asset Management Partners’s Immunovant IMVT Stock Holding History

Polar Asset Management Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,300
Closed -$1.99M – 770
2024
Q2 		$1.99M Buy
75,300
+23,800
+46% +$677K 0.04% 329
2024
Q1 		$1.66M Buy
51,500
+39,400
+326% +$1.44M 0.03% 383
2023
Q4 		$510K Sell
12,100
-143,400
-92% -$5.28M 0.01% 465
2023
Q3 		$5.97M Buy
155,500
+500
+0.3% +$11.3K 0.13% 195
2023
Q2 		$2.94M Sell
155,000
-373,000
-71% -$6.96M 0.05% 408
2023
Q1 		$8.19M Hold
528,000
– – 0.12% 217
2022
Q4 		$9.37M Buy
+528,000
New +$6.65M 0.11% 253
2022
Q2 		– Sell
-348,400
Closed -$1.92M – 1384
2022
Q1 		$1.92M Hold
348,400
– – 0.02% 645
2021
Q4 		$2.97M Buy
348,400
+237,600
+214% +$1.96M 0.03% 539
2021
Q3 		$963K Buy
+110,800
New +$1,000K 0.01% 697

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Polar Asset Management Partners's IMVT Position: Q3 2024 in Review

Polar Asset Management Partners sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 75,300 shares — an estimated $1.99M sold.

Polar Asset Management Partners first reported a position in IMVT in Q3 2021 and held it in 10 quarters. The position peaked at $9.37M in Q4 2022. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Polar Asset Management Partners reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 75,300 Immunovant shares in Q3 2024, an estimated $1.99M.
  • Polar Asset Management Partners first reported a position in Immunovant in Q3 2021 and held it in 10 quarters.
  • Polar Asset Management Partners's Immunovant position peaked at $9.37M in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Polar Asset Management Partners's 13F filing for Q3 2024, filed 14 Nov 2024.